AXSM Axsome Therapeutics
- 88.840
- -0.190-0.21%
- 88.840
- 0.0000.00%
Axsome Therapeutics News
Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment?
Axsome Therapeutics Presents Data From Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Optimistic Outlook for Axsome Therapeutics' Auvelity Amid Steady Prescription Growth
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Positive Buy Recommendation for Axsome Therapeutics Driven by Promising AXS-05 Efficacy in Alzheimer's Agitation
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Buy Rating Justified for Axsome Therapeutics Amidst Strong Auvelity Launch and Promising Sales Trajectory
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $106
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
The Five-year Returns Have Been Enviable for Axsome Therapeutics (NASDAQ:AXSM) Shareholders Despite Underlying Losses Increasing
Express News | Axsome Therapeutics: Fifth Amendment to Increase Tranche 3 Commitment From $75 to $80 Mln
Express News | Axsome Therapeutics: On September 30 Entered Into Fifth Amendment to Its Loan & Security Agreement Dated Sept 25, 2020
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Axsome Therapeutics Added to Q4 2024 Tactical Ideas List at Wells Fargo
Buy Rating Justified for Axsome Therapeutics Amidst Strong Market Opportunities and Promising Trial Outcomes
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Analysis
Price Target
No Data
No Data